A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Inclusion Criteria

• •Participant 18-60 years of age, inclusive, at Screening;
• •Able to understand the key components of the study as described in the written informed consent document, and willing and able to provide written informed consent;
• •Body mass index (BMI) within the range of 18.5 to 32 kg/m2 at Screening;
• •Participants assigned male at birth (AMAB) will be either sterile or agree to use an approved method of contraception from Screening until at least 5 half-lives plus 90 days after the last dose of study drug, or do not engage in sexual relations which carry a risk of pregnancy (does include abstinence), and agree to refrain from sperm donation and in vitro fertilization until 5 half-lives plus 90 days after the last dose of the study drug;
• •In the opinion of the Investigator, is able to adhere to the requirements of the study, including required overnight stays in the research site.